Journal of Bone and Mineral Research · 1995 · 105 citations · 26 references
MedicineEndocrinologyOrthopedic SurgeryBone MetabolismMineral MetabolismPediatric OrthopaedicsBone DisordersBone GrowthBone HistomorphometryBone MineralizationBone PathologyOsteoporosisBone Mineral DensityBone Mineral Density AssessmentBone Volume EvaluationBone Volume MeasurementInsulin-like Growth Factor-1Mineralized Bone SurfaceOsteoid SurfaceOsteoid Volume
We have previously reported that bone formation is impaired on histomorphometric analysis of bone in patients with idiopathic osteoporosis. In the present study, 30 patients with idiopathic osteoporosis (18 men and 12 women mean age 44 +/- 12 years) and spinal and/or appendicular fractures were studied. Compared with control values, bone biopsy analysis demonstrated reduced bone volume (13.0 +/- 4.4 vs. 23.2 +/- 4.4, p < 0.0001), osteoid volume (0.13 +/- 0.13 vs. 0.32 +/- 0.19, p = 0.001), osteoid surface (5.9 +/- 4.3 vs. 12.1 +/- 4.6, p = 0.0004), and diminished double-labeled mineralizing surface (MS/BS 2.0 +/- 2.1 vs. 5.1 +/- 2.7%, p = 0.0001) in the patients. Since insulin-like growth factor 1 (IGF-1) is one of the major determinants of bone growth and remodeling, we measured the circulating level of this growth factor in these patients. The mean serum IGF-1 concentration was lower in patients as compared with 33 healthy age-matched controls (193 +/- 59 SD ng/ml vs. 232 +/- 79). A significant difference was noted between the two groups only in subjects younger than 36 years. In patients with idiopathic osteoporosis, regression analysis of serum IGF-1 against the various histological parameters measured from the bone biopsy disclosed significant correlation's between serum IGF-1 and osteoblastic surface (r = 0.429, p = 0.032), mineralizing bone surface with a double label (r = 0.480, p = 0.015), and the bone formation rate (r = 0.457, p = 0.021). These findings suggest that in young eugonadal individuals with idiopathic osteoporosis, reduced IGF-1 concentrations may have an etiological role in the development of this disease.
26
B. Lawrence Riggs, Heinz W. Wahner, Richard B. Mazess et al. · Journal of Clinical Investigation · 1981 · 1.2K citations · Full text
LONG-TERM PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS BY ŒSTROGEN
R. Lindsay, J. M. Aitken, L.B. Anderson et al. · The Lancet · 1976 · 956 citations
Timothy A. Reinhardt, Ronald L. Horst, John W. Orf et al. · The Journal of Clinical Endocrinology & Metabolism · 1984 · 805 citations